Overexpression of MUC1 predicts poor prognosis in patients with breast cancer
Breast cancer is the most commonly diagnosed cancer in females; thus, there is an urgent requirement to identify precise biomarkers for the diagnosis and treatment of the disease. Mucin 1 (MUC1) is a glycoprotein that has been demonstrated to be involved in the metastasis and invasion of multiple tu...
Gespeichert in:
Veröffentlicht in: | Oncology reports 2019-02, Vol.41 (2), p.801-810 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 810 |
---|---|
container_issue | 2 |
container_start_page | 801 |
container_title | Oncology reports |
container_volume | 41 |
creator | Jing, Xuan Liang, Hongping Hao, Chonghua Yang, Xiaojuan Cui, Xiangrong |
description | Breast cancer is the most commonly diagnosed cancer in females; thus, there is an urgent requirement to identify precise biomarkers for the diagnosis and treatment of the disease. Mucin 1 (MUC1) is a glycoprotein that has been demonstrated to be involved in the metastasis and invasion of multiple tumor types. Bioinformatics analyses were conducted to indicate the prognostic value of MUC1 in breast cancer. Additionally, the expression level of MUC1 was assessed using Oncomine analysis. Furthermore, PrognoScan was used to analyze the prognostic value of MUC1 in breast cancer. Mutations of MUC1 were analyzed by the Catalogue of Somatic Mutations in Cancer and cBioPortal databases. In addition, University of California, Santa Cruz (UCSC) was used to examine the methylation status of MUC1. Co‑expression of MUC1 mRNA was detected with the cBioPortal, UCSC and Breast Cancer Gene‑Expression Miner v4.0 datasets. The results demonstrated that MCU1 is frequently overexpressed in breast cancer and is negatively associated with CpG sites. Furthermore, pooled data indicated that abnormally high expression of MUC1 indicates poor prognosis. Additionally, upregulation of MUC1 expression is associated with estrogen receptor‑ and progesterone receptor‑positive disease, aging and increased Scarff, Bloom and Richardson grade, but is not associated with triple‑negative and basal‑like status. Subsequent data mining across multiple large databases demonstrated a positive association between MUC1 mRNA expression and cyclic AMP‑responsive element‑binding protein 3‑like 4 (CREB3L4) in breast cancer tissues. The present data indicated that the overexpression of MUC1 indicates a poor prognosis in patients with breast cancer and is associated with MUC1 promoter methylation status. Additionally, MUC1 positively correlated with CREB3L4 and may serve as a potential prognostic factor and therapy target for breast cancer. |
doi_str_mv | 10.3892/or.2018.6887 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6313072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A570200315</galeid><sourcerecordid>A570200315</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-9bdd8de568c572b2d68ee093b7d9323cc893e138cf84d88603a6aa349a18e5383</originalsourceid><addsrcrecordid>eNptkk1r3DAQhk1paNK0t56LoVB6qLeSxpalSyEs_Qgk5NJAb0KWxrsKXsmV7CT995VJGnZL0UHSzDPv6OMtijeUrEBI9inEFSNUrLgQ7bPihLaSVqwG-jyvCaMVQPPzuHiZ0g0hrCVcviiOgdQCBOEnxeXVLUa8HyOm5IIvQ19eXq9pmQPWmSmVYwgx78LGh-RS6Xw56smhz6k7N23LLqJOU2m0NxhfFUe9HhK-fpxPi-uvX36sv1cXV9_O12cXlWkomSrZWSssNlyYpmUds1wgEgldayUwMEZIQArC9KK2QnACmmsNtdRUYAMCTovPD7rj3O3QmnycqAc1RrfT8bcK2qnDjHdbtQm3igMF0rIs8OFRIIZfM6ZJ7VwyOAzaY5iTYrk7z43kgr77B70Jc_T5epniTNaU0T1qowdUzvch9zWLqDprWsIIAdpkavUfKg-LO2eCx97l-EHB-72CLeph2qYwzFP-q3QIfnwATQwpReyfHoMStfhEhagWn6jFJxl_u_-AT_BfY8Af4OK2fA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2162941212</pqid></control><display><type>article</type><title>Overexpression of MUC1 predicts poor prognosis in patients with breast cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Jing, Xuan ; Liang, Hongping ; Hao, Chonghua ; Yang, Xiaojuan ; Cui, Xiangrong</creator><creatorcontrib>Jing, Xuan ; Liang, Hongping ; Hao, Chonghua ; Yang, Xiaojuan ; Cui, Xiangrong</creatorcontrib><description>Breast cancer is the most commonly diagnosed cancer in females; thus, there is an urgent requirement to identify precise biomarkers for the diagnosis and treatment of the disease. Mucin 1 (MUC1) is a glycoprotein that has been demonstrated to be involved in the metastasis and invasion of multiple tumor types. Bioinformatics analyses were conducted to indicate the prognostic value of MUC1 in breast cancer. Additionally, the expression level of MUC1 was assessed using Oncomine analysis. Furthermore, PrognoScan was used to analyze the prognostic value of MUC1 in breast cancer. Mutations of MUC1 were analyzed by the Catalogue of Somatic Mutations in Cancer and cBioPortal databases. In addition, University of California, Santa Cruz (UCSC) was used to examine the methylation status of MUC1. Co‑expression of MUC1 mRNA was detected with the cBioPortal, UCSC and Breast Cancer Gene‑Expression Miner v4.0 datasets. The results demonstrated that MCU1 is frequently overexpressed in breast cancer and is negatively associated with CpG sites. Furthermore, pooled data indicated that abnormally high expression of MUC1 indicates poor prognosis. Additionally, upregulation of MUC1 expression is associated with estrogen receptor‑ and progesterone receptor‑positive disease, aging and increased Scarff, Bloom and Richardson grade, but is not associated with triple‑negative and basal‑like status. Subsequent data mining across multiple large databases demonstrated a positive association between MUC1 mRNA expression and cyclic AMP‑responsive element‑binding protein 3‑like 4 (CREB3L4) in breast cancer tissues. The present data indicated that the overexpression of MUC1 indicates a poor prognosis in patients with breast cancer and is associated with MUC1 promoter methylation status. Additionally, MUC1 positively correlated with CREB3L4 and may serve as a potential prognostic factor and therapy target for breast cancer.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2018.6887</identifier><identifier>PMID: 30483806</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Age Factors ; Basic-Leucine Zipper Transcription Factors - metabolism ; Biomarkers ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Breast cancer ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer therapies ; Care and treatment ; Cell adhesion & migration ; Computational Biology ; CpG Islands - genetics ; Data Mining ; Databases, Genetic ; Datasets ; Datasets as Topic ; Development and progression ; Epidermal growth factor ; Female ; Gene expression ; Genetic aspects ; Genomes ; Genomics ; Glycoproteins ; Health aspects ; Humans ; Medical prognosis ; Medical research ; Metastasis ; Middle Aged ; Mucin-1 - genetics ; Mucin-1 - metabolism ; Mucins ; Mutation ; Nuclear Proteins - metabolism ; Prognosis ; Promoter Regions, Genetic ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; RNA, Messenger - metabolism ; Survival Analysis ; Transcription factors ; Tumors</subject><ispartof>Oncology reports, 2019-02, Vol.41 (2), p.801-810</ispartof><rights>COPYRIGHT 2019 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2019</rights><rights>Copyright: © Jing et al. 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-9bdd8de568c572b2d68ee093b7d9323cc893e138cf84d88603a6aa349a18e5383</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30483806$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jing, Xuan</creatorcontrib><creatorcontrib>Liang, Hongping</creatorcontrib><creatorcontrib>Hao, Chonghua</creatorcontrib><creatorcontrib>Yang, Xiaojuan</creatorcontrib><creatorcontrib>Cui, Xiangrong</creatorcontrib><title>Overexpression of MUC1 predicts poor prognosis in patients with breast cancer</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Breast cancer is the most commonly diagnosed cancer in females; thus, there is an urgent requirement to identify precise biomarkers for the diagnosis and treatment of the disease. Mucin 1 (MUC1) is a glycoprotein that has been demonstrated to be involved in the metastasis and invasion of multiple tumor types. Bioinformatics analyses were conducted to indicate the prognostic value of MUC1 in breast cancer. Additionally, the expression level of MUC1 was assessed using Oncomine analysis. Furthermore, PrognoScan was used to analyze the prognostic value of MUC1 in breast cancer. Mutations of MUC1 were analyzed by the Catalogue of Somatic Mutations in Cancer and cBioPortal databases. In addition, University of California, Santa Cruz (UCSC) was used to examine the methylation status of MUC1. Co‑expression of MUC1 mRNA was detected with the cBioPortal, UCSC and Breast Cancer Gene‑Expression Miner v4.0 datasets. The results demonstrated that MCU1 is frequently overexpressed in breast cancer and is negatively associated with CpG sites. Furthermore, pooled data indicated that abnormally high expression of MUC1 indicates poor prognosis. Additionally, upregulation of MUC1 expression is associated with estrogen receptor‑ and progesterone receptor‑positive disease, aging and increased Scarff, Bloom and Richardson grade, but is not associated with triple‑negative and basal‑like status. Subsequent data mining across multiple large databases demonstrated a positive association between MUC1 mRNA expression and cyclic AMP‑responsive element‑binding protein 3‑like 4 (CREB3L4) in breast cancer tissues. The present data indicated that the overexpression of MUC1 indicates a poor prognosis in patients with breast cancer and is associated with MUC1 promoter methylation status. Additionally, MUC1 positively correlated with CREB3L4 and may serve as a potential prognostic factor and therapy target for breast cancer.</description><subject>Age Factors</subject><subject>Basic-Leucine Zipper Transcription Factors - metabolism</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell adhesion & migration</subject><subject>Computational Biology</subject><subject>CpG Islands - genetics</subject><subject>Data Mining</subject><subject>Databases, Genetic</subject><subject>Datasets</subject><subject>Datasets as Topic</subject><subject>Development and progression</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mucin-1 - genetics</subject><subject>Mucin-1 - metabolism</subject><subject>Mucins</subject><subject>Mutation</subject><subject>Nuclear Proteins - metabolism</subject><subject>Prognosis</subject><subject>Promoter Regions, Genetic</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>RNA, Messenger - metabolism</subject><subject>Survival Analysis</subject><subject>Transcription factors</subject><subject>Tumors</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkk1r3DAQhk1paNK0t56LoVB6qLeSxpalSyEs_Qgk5NJAb0KWxrsKXsmV7CT995VJGnZL0UHSzDPv6OMtijeUrEBI9inEFSNUrLgQ7bPihLaSVqwG-jyvCaMVQPPzuHiZ0g0hrCVcviiOgdQCBOEnxeXVLUa8HyOm5IIvQ19eXq9pmQPWmSmVYwgx78LGh-RS6Xw56smhz6k7N23LLqJOU2m0NxhfFUe9HhK-fpxPi-uvX36sv1cXV9_O12cXlWkomSrZWSssNlyYpmUds1wgEgldayUwMEZIQArC9KK2QnACmmsNtdRUYAMCTovPD7rj3O3QmnycqAc1RrfT8bcK2qnDjHdbtQm3igMF0rIs8OFRIIZfM6ZJ7VwyOAzaY5iTYrk7z43kgr77B70Jc_T5epniTNaU0T1qowdUzvch9zWLqDprWsIIAdpkavUfKg-LO2eCx97l-EHB-72CLeph2qYwzFP-q3QIfnwATQwpReyfHoMStfhEhagWn6jFJxl_u_-AT_BfY8Af4OK2fA</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Jing, Xuan</creator><creator>Liang, Hongping</creator><creator>Hao, Chonghua</creator><creator>Yang, Xiaojuan</creator><creator>Cui, Xiangrong</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190201</creationdate><title>Overexpression of MUC1 predicts poor prognosis in patients with breast cancer</title><author>Jing, Xuan ; Liang, Hongping ; Hao, Chonghua ; Yang, Xiaojuan ; Cui, Xiangrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-9bdd8de568c572b2d68ee093b7d9323cc893e138cf84d88603a6aa349a18e5383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Age Factors</topic><topic>Basic-Leucine Zipper Transcription Factors - metabolism</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell adhesion & migration</topic><topic>Computational Biology</topic><topic>CpG Islands - genetics</topic><topic>Data Mining</topic><topic>Databases, Genetic</topic><topic>Datasets</topic><topic>Datasets as Topic</topic><topic>Development and progression</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mucin-1 - genetics</topic><topic>Mucin-1 - metabolism</topic><topic>Mucins</topic><topic>Mutation</topic><topic>Nuclear Proteins - metabolism</topic><topic>Prognosis</topic><topic>Promoter Regions, Genetic</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>RNA, Messenger - metabolism</topic><topic>Survival Analysis</topic><topic>Transcription factors</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Jing, Xuan</creatorcontrib><creatorcontrib>Liang, Hongping</creatorcontrib><creatorcontrib>Hao, Chonghua</creatorcontrib><creatorcontrib>Yang, Xiaojuan</creatorcontrib><creatorcontrib>Cui, Xiangrong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jing, Xuan</au><au>Liang, Hongping</au><au>Hao, Chonghua</au><au>Yang, Xiaojuan</au><au>Cui, Xiangrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of MUC1 predicts poor prognosis in patients with breast cancer</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>41</volume><issue>2</issue><spage>801</spage><epage>810</epage><pages>801-810</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Breast cancer is the most commonly diagnosed cancer in females; thus, there is an urgent requirement to identify precise biomarkers for the diagnosis and treatment of the disease. Mucin 1 (MUC1) is a glycoprotein that has been demonstrated to be involved in the metastasis and invasion of multiple tumor types. Bioinformatics analyses were conducted to indicate the prognostic value of MUC1 in breast cancer. Additionally, the expression level of MUC1 was assessed using Oncomine analysis. Furthermore, PrognoScan was used to analyze the prognostic value of MUC1 in breast cancer. Mutations of MUC1 were analyzed by the Catalogue of Somatic Mutations in Cancer and cBioPortal databases. In addition, University of California, Santa Cruz (UCSC) was used to examine the methylation status of MUC1. Co‑expression of MUC1 mRNA was detected with the cBioPortal, UCSC and Breast Cancer Gene‑Expression Miner v4.0 datasets. The results demonstrated that MCU1 is frequently overexpressed in breast cancer and is negatively associated with CpG sites. Furthermore, pooled data indicated that abnormally high expression of MUC1 indicates poor prognosis. Additionally, upregulation of MUC1 expression is associated with estrogen receptor‑ and progesterone receptor‑positive disease, aging and increased Scarff, Bloom and Richardson grade, but is not associated with triple‑negative and basal‑like status. Subsequent data mining across multiple large databases demonstrated a positive association between MUC1 mRNA expression and cyclic AMP‑responsive element‑binding protein 3‑like 4 (CREB3L4) in breast cancer tissues. The present data indicated that the overexpression of MUC1 indicates a poor prognosis in patients with breast cancer and is associated with MUC1 promoter methylation status. Additionally, MUC1 positively correlated with CREB3L4 and may serve as a potential prognostic factor and therapy target for breast cancer.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>30483806</pmid><doi>10.3892/or.2018.6887</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1021-335X |
ispartof | Oncology reports, 2019-02, Vol.41 (2), p.801-810 |
issn | 1021-335X 1791-2431 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6313072 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Age Factors Basic-Leucine Zipper Transcription Factors - metabolism Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer therapies Care and treatment Cell adhesion & migration Computational Biology CpG Islands - genetics Data Mining Databases, Genetic Datasets Datasets as Topic Development and progression Epidermal growth factor Female Gene expression Genetic aspects Genomes Genomics Glycoproteins Health aspects Humans Medical prognosis Medical research Metastasis Middle Aged Mucin-1 - genetics Mucin-1 - metabolism Mucins Mutation Nuclear Proteins - metabolism Prognosis Promoter Regions, Genetic Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism RNA, Messenger - metabolism Survival Analysis Transcription factors Tumors |
title | Overexpression of MUC1 predicts poor prognosis in patients with breast cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A33%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20MUC1%20predicts%20poor%20prognosis%20in%20patients%20with%20breast%20cancer&rft.jtitle=Oncology%20reports&rft.au=Jing,%20Xuan&rft.date=2019-02-01&rft.volume=41&rft.issue=2&rft.spage=801&rft.epage=810&rft.pages=801-810&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2018.6887&rft_dat=%3Cgale_pubme%3EA570200315%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2162941212&rft_id=info:pmid/30483806&rft_galeid=A570200315&rfr_iscdi=true |